Chimeric antigen receptors (CARs) designed for adoptive immunotherapy need to achieve two functions: antigen recognition and triggering of the lytic machinery of reprogrammed effector cells. Cytotoxic T cells have been engineered with FcγRIII (CD16) chimeric molecules to be redirected against malignant cells by monoclonal antibodies (mAbs). These cells have been proven to mediate granule-dependent cellular cytotoxicity, but it is not clear whether they can also kill malignant cells by a granule-independent mechanism of cell cytotoxicity.

D'Aloia, M., Caratelli, S., Palumbo, C., Battella, S., Arriga, R., Lauro, D., et al. (2016). T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. CYTOTHERAPY, 18(2), 278-290 [10.1016/j.jcyt.2015.10.014].

T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells

PALUMBO, CAMILLA;ARRIGA, ROBERTO;LAURO, DAVIDE;
2016-02

Abstract

Chimeric antigen receptors (CARs) designed for adoptive immunotherapy need to achieve two functions: antigen recognition and triggering of the lytic machinery of reprogrammed effector cells. Cytotoxic T cells have been engineered with FcγRIII (CD16) chimeric molecules to be redirected against malignant cells by monoclonal antibodies (mAbs). These cells have been proven to mediate granule-dependent cellular cytotoxicity, but it is not clear whether they can also kill malignant cells by a granule-independent mechanism of cell cytotoxicity.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13 - Endocrinologia
eng
Con Impact Factor ISI
CD16; CD28; Fas ligand; FcγR; MD45 cells; TCR; chimeric antigen receptors; ζ-chain
D'Aloia, M., Caratelli, S., Palumbo, C., Battella, S., Arriga, R., Lauro, D., et al. (2016). T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. CYTOTHERAPY, 18(2), 278-290 [10.1016/j.jcyt.2015.10.014].
D'Aloia, M; Caratelli, S; Palumbo, C; Battella, S; Arriga, R; Lauro, D; Palmieri, G; Sconocchia, G; Alimandi, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Cytotherapy 2016.pdf

non disponibili

Descrizione: Articolo principale
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1.6 MB
Formato Adobe PDF
1.6 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/157227
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 26
social impact